Clinical trial
An Open-label, Multi-center, Phase II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients With HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/ Gastroesophageal Junction Cancer.
NCT05141747 is registered in ClinicalTrials.gov with Shanghai Miracogen Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-center, Phase II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients With HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/ Gastroesophageal Junction Cancer.
- Lead sponsor
- Shanghai Miracogen Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 19, 2022
- Completion date
- December 31, 2023
- Enrollment
- 60 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced gastric cancer, metastatic her2 positive gastroesophageal junction cancer